ARS Pharmaceuticals Announces Key Executive Leadership Departures
I'm LongbridgeAI, I can summarize articles.ARS Pharmaceuticals announced key executive departures on July 15, 2026. Board member Richard Lowenthal resigned immediately, and Chief Medical Officer Sarina Tanimoto ceased employment without cause. Both received severance payments of $217,350 and $111,780 respectively, contingent on claim releases. This marks notable leadership changes for the biopharmaceutical company.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
An update from ARS Pharmaceuticals ( (SPRY) ) is now available.
On July 15, 2026, ARS Pharmaceuticals announced that Board member Richard Lowenthal resigned from the Board, effective immediately, as part of conditions tied to his severance compensation under his employment agreement and the company’s Change in Control and Severance Benefit Plan. On the same date, Chief Medical Officer Sarina Tanimoto, M.D., ceased employment under a termination without cause, marking notable leadership changes for the biopharmaceutical company.
In addition to severance benefits already outlined in prior corporate disclosures, ARS Pharmaceuticals agreed to provide Mr. Lowenthal and Dr. Tanimoto one-time payments of $217,350 and $111,780, respectively, reflecting prorated portions of their 2026 target bonuses. These payments, together with the severance arrangements, are contingent on the effectiveness of releases of claims by both former executives, underscoring the company’s structured approach to executive transitions and risk management.
The most recent analyst rating on (SPRY) stock is a Buy
with a $30.00 price target.
To see the full list of analyst forecasts on ARS Pharmaceuticals stock,
see the SPRY Stock Forecast page.
Spark’s Take on SPRY Stock
According to Spark, TipRanks’ AI Analyst, SPRY is a Neutral.
The score is held back primarily by weak financial performance driven by large ongoing losses and substantial cash burn, alongside technically weak price momentum below key moving averages. These are partially offset by a constructive earnings-call outlook highlighting strong prescription/revenue momentum, improving payer access initiatives, and a sizable cash position with a stated path toward cash-flow breakeven.
To see Spark’s full report on SPRY stock,
click here.
More about ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. operates in the biopharmaceutical sector, focusing on the development of drug products for allergic and respiratory conditions. The company’s leadership and governance structure, including its Board of Directors and executive team, play a central role in advancing its clinical and commercial strategy in these specialized therapeutic areas.
Average Trading Volume: 1,839,616
Technical Sentiment Signal: Sell
Current Market Cap: $740.8M